BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hospital of St. Raphael To Offer AusAm Biotechnologies's Urine Test For Indicator Of Kidney Disease


10/19/2005 5:10:54 PM

NEW HAVEN, Conn.--(BUSINESS WIRE)--April 14, 2004-- Accumin(TM) Provides the First Direct Total Intact Measurement of Protein Albumin in Urine

AusAm Biotechnologies, Inc. today announced that the Hospital of St. Raphael will now offer AusAm's FDA-cleared diagnostic, Accumin(TM) Direct Total Intact Albumin Assay (HPLC)(TM) for detection of the protein albumin in urine. St. Raphael's is part of AusAm's "Centers of Excellence" program to increase access to the Accumin albumin test through influential medical institutions and labs. An excess of albumin in urine, a condition known as microalbuminuria, could be an early warning sign of kidney disease.

"Kidney disease is a widespread medical condition that affects more than 20 million Americans," said Dr. David Stair, a certified specialist in clinical hypertension and a clinical instructor at the Yale University School of Medicine. "It is clear from clinical research that microalbuminuria is an indicator of kidney and other diseases; the earlier we can detect microalbuminuria, the better chance we have of helping our patients at risk."

Traditional urine tests do not directly measure albumin. According to a study published in the American Journal of Kidney Diseases, traditional indirect measurement may "severely underestimate" the amount of albumin in the urine of certain patients. In this study, Accumin identified the presence of microalbuminuria in 33 percent of urine samples from diabetic patients where the conventional urine testing showed normal levels. As with other albumin assays, repeated measurements of excretion rates with Accumin over a period of time are appropriate because of high variability of albumin excretion.

"The Hospital of St. Raphael is an award-winning medical center affiliated with the prestigious Yale University School of Medicine. We look forward to working with physicians at St. Raphael's and Yale to make Accumin accessible to patients in the Connecticut area," said James McCullough, Chief Executive Officer of AusAm Biotechnologies, Inc. "Our goal with the Centers of Excellence program is to make Accumin the standard of care for patients across the country, and we are delighted St. Raphael's is a part of this effort."

When kidney disease is identified in its initial stages, clinical evidence shows that its progression may be slowed, halted, and, in some cases, reversed with appropriate drug therapies. Patients considered at risk include those with diabetes and hypertension. Diabetes is the single leading cause of kidney failure in the U.S., accounting for more than 44 percent of the people who start treatment for kidney failure each year. The National Kidney Foundation recommends that everyone with diabetes between the ages of 12 and 70 years have a urine test for microalbuminuria at least once a year.

About Accumin(TM) Direct Total Intact Albumin Assay (HPLC)(TM)

Cleared by the U.S. Food and Drug Administration in August 2003, Accumin was developed by AusAm Biotechnologies as a step-change improvement over conventional tests for microalbuminuria. Accumin uses common laboratory equipment to separate intact albumin from the other compounds in urine and directly determine its quantity. Accumin is relatively inexpensive and is reimbursable by Medicare where medically reasonable and necessary. Patients who are interested in more information should consult their physicians about Accumin, or go to www.ausambiotech.com.

About the Hospital of St. Raphael

The Hospital of Saint Raphael is a 511-bed acute care community teaching hospital affiliated with Yale University School of Medicine. A leader in cardiac, cancer, orthopedic, neuroscience and geriatric services, Saint Raphael's is the largest member of the Saint Raphael Healthcare System.

About AusAm Biotechnologies, Inc.

AusAm is a biotechnology research and development company commercializing both diagnostic and therapeutic products to identify and treat major diseases. AusAm's recently FDA-cleared diagnostic for the detection of intact albumin in urine is the first direct test to measure a potential indicator of the beginning stages of kidney disease and it is currently offered by several reference laboratories and hospitals in the United States. For additional information, please contact AusAm at 212-659-0703 or email inquiries to info@ausambiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements with respect to management's beliefs about the business of AusAm in the future. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to the ability of AusAm to successfully implement the strategy of AusAm. AusAm undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unexpected results.

Contacts

Schwartz Communications Wendy Williams or Amy Kramer, 781-684-0770 ausam@schwartz-pr.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES